Osteopore Ltd
ASX:OSX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Osteopore Ltd
Cash from Operating Activities
Osteopore Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Osteopore Ltd
ASX:OSX
|
Cash from Operating Activities
-AU$2.5m
|
CAGR 3-Years
14%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Nanosonics Ltd
ASX:NAN
|
Cash from Operating Activities
AU$29.4m
|
CAGR 3-Years
23%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Polynovo Ltd
ASX:PNV
|
Cash from Operating Activities
AU$24.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
132%
|
CAGR 10-Years
N/A
|
|
|
SDI Ltd
ASX:SDI
|
Cash from Operating Activities
AU$14.6m
|
CAGR 3-Years
28%
|
CAGR 5-Years
4%
|
CAGR 10-Years
8%
|
|
|
Anteris Technologies Ltd
ASX:AVR
|
Cash from Operating Activities
-AU$78m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
N/A
|
|
|
Ansell Ltd
ASX:ANN
|
Cash from Operating Activities
$277.5m
|
CAGR 3-Years
4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
4%
|
|
Osteopore Ltd
Glance View
Osteopore Ltd. develops and markets bioresorbable polymer implants for neurosurgical, orthopaedic and maxillofacial surgeries. The company is headquartered in Perth, Western Australia. The company went IPO on 2019-09-23. The firm is engaged in commercializing a range of products to facilitate bone healing across multiple therapeutic areas. The company fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material using its platform technology. Its 3D print scaffold design is based on the principle of tissue engineering and regenerative medicine. Its craniofacial products include Osteomesh, Osteoplug, and Osteoplug-C. Its craniofacial products are used as bone void fillers for regeneration of natural bone. The company also develops and manufactures implants that focuses on unmet clinical needs which improve patient outcomes. Its science of tissue engineering and regenerative medicine provides various surgical solutions for medical surgeons. Its products are used by surgeons across Asia, Europe, Australia, and the Americas.
See Also
What is Osteopore Ltd's Cash from Operating Activities?
Cash from Operating Activities
-2.5m
AUD
Based on the financial report for Dec 31, 2025, Osteopore Ltd's Cash from Operating Activities amounts to -2.5m AUD.
What is Osteopore Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-8%
Over the last year, the Cash from Operating Activities growth was 18%. The average annual Cash from Operating Activities growth rates for Osteopore Ltd have been 14% over the past three years , -8% over the past five years .
